Esmat SM, El-Mofty M, Rasheed H, et al. - In vitiligo cases where corticosteroids are contraindicated or immune-suppression is unjustified, the only well-established therapy that can be employed solely is NB-UVB. Together with corticosteroids, NB-UVB not only expedites response but also improves compliance.

• In this multicenter, placebo-controlled, randomized, prospective study, 80 patients with active nonsegmental vitiligo (Vitiligo disease activity ≥2) were included.

• They were randomly assigned to either NB-UVB and placebo (NB-placebo) or NB-UVB and dexamethasone oral mini-pulse (OMP) therapy (NB-OMP) for 6 months; 64 patients completed the study, 34 in the NB-OMP group and 30 in the NB-placebo group.

• In the NB-OMP group, earlier control of disease activity was evident, but it was comparable in both groups by the end of the study span.

• There was an impact of disease activity before therapy on the control of activity in both groups.

• NB-UVB affords a safe vitiligo therapy and it efficiently achieves repigmentation and represents a comparable stabilizing tool for systemic corticosteroids in spite of slightly delayed control.